Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/23/2019 |
| Start Date: | April 2019 |
| End Date: | July 2022 |
Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study
To determine if Carevive software, which monitors treatment-related toxicities and then
generates self-care management plans for these symptoms, will be feasible to implement among
patients with metastatic renal cell carcinoma (RCC). Additionally for collection of
preliminary data on treatment-related toxicities, quality of life, distress level, and drug
adherence.
generates self-care management plans for these symptoms, will be feasible to implement among
patients with metastatic renal cell carcinoma (RCC). Additionally for collection of
preliminary data on treatment-related toxicities, quality of life, distress level, and drug
adherence.
Inclusion Criteria:
- Diagnosis of histologically confirmed renal cell carcinoma of any subtype with either
pathological or radiographic evidence of metastatic disease
- Greater than 18 years of age
- A participating Wilmot Cancer Center oncologist has determined that candidate should
be started on either oral targeted therapy or immunotherapy for treatment of their
advanced RCC; this can be for first-line or any subsequent line therapy
- Able to provide written informed consent
- Proficient in the English language and self-reports as literate
- Must have an active email address or access to a smart device on which text messages
can be received
Exclusion Criteria:
- Women cannot be breast-feeding
- Does not have regular access to the internet
- Unable to come to the Wilmot Cancer Center for appointments every 3-4 months for
routine visits with their primary oncologist
- Subjects who were on the study previously will not be allowed to re-enroll in the
event of a treatment change
We found this trial at
1
site
Click here to add this to my saved trials
